Finch Therapeutics

Executive Summary

Finch Therapeutics is a pioneer in microbiome-based therapeutics, leveraging its proprietary platform to develop live biotherapeutic products (LBPs) for conditions with high unmet need. The company's lead candidate, CP101, is a full-spectrum microbiome therapeutic designed to prevent recurrent C. difficile infection (rCDI). In Phase 2, CP101 demonstrated statistically significant reduction in recurrence versus placebo, but the response rate was modest, leading to a pivot toward a more targeted formulation. Finch is now advancing CP101 into a Phase 3 trial with refined patient selection and dosing, aiming to confirm efficacy and support a Biologics License Application (BLA). Beyond rCDI, the company has preclinical programs in inflammatory bowel disease and autism spectrum disorder, though these are earlier stage. As a private company, Finch has secured funding from top-tier investors and strategic partners, allowing it to navigate the challenging regulatory pathway for microbiome drugs. The company's success hinges on the pivotal data readout, which could validate the microbiome approach and unlock significant value.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 CP101 top-line data in recurrent C. difficile infection55% success
• Q2 2026Initiation of Phase 2 trial for CP101 in inflammatory bowel disease40% success
• TBDPotential partnership or licensing deal for preclinical autism program35% success